November 11, 2021 The quest for efficacy in pancreatic cancer Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
October 24, 2012 Therapeutic Focus – Liver cancer focus switches to second-line as Nexavar proves a tough nut to crack
